We use our own and third-party cookies to optimize your experience on this site, including to maintain user sessions. Without these cookies our site will not function well. If you continue browsing our site we take that to mean that you understand and accept how we use the cookies. If you wish to decline our cookies we will redirect you to Google.
Already have an account? Sign in.

 Remember Me | Forgot Your Password?

GSK-Developed Antiseptic Chlorhexidine Gel For Prevention Of Umbilical Cord Infections Receives European Agency's Endorsement

April 29, 2016: 12:00 AM EST
An antiseptic chlorhexidine gel, developed through a partnership between GSK and Save the Children and designed to prevent umbilical cord infections in newborn infants in developing countries, has received a positive scientific opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency. Caused by bacteria entering the body through a newly cut umbilical cord, omphalitis is a leading cause of infant mortality in developing countries. GSK reformulated the antiseptic solution used in its Corsodyl mouthwash into a gel, integrating Save the Children’s capabilities in reaching some of the world’s most at-risk children. GSK plans to submit applications for government approval for the gel, which will be distributed under the Umbipro brand, in low-income countries with moderate to high rates of neonatal deaths.
"European agency endorses antiseptic gel, developed through GSK and Save the Children partnership, for newborn umbilical cord infections in developing countries", GlaxoSmithKline , April 29, 2016, © GlaxoSmithKline plc
Market Segments
Products & Pricing
Baby Care
Companies, Organizations
Legal, Legislation, Regulation, Policy
Press Release
Products & Brands
Developed by Yuri Ingultsov Software Lab.